The Quantellect read.As of Nov 20, 2026, 12 active firms cover Arcus Biosciences Inc: 9 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $22.00 to $49.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $37.91 sits 140% above the current $15.78. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.88 next quarter toward $-3.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy00%
Buy975%
Neutral325%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$37.91
+140.2% upside
Average target across 11 active firms as of Nov 20, 2026 vs $15.78 current
Highest Target$49.00
Average Target$37.91
Lowest Target$22.00
Detailed analyst forecasts for RCUS
Showing 1–12 of 12 named analysts shown · 12 active firms in the rating projection
As of Nov 20, 2026, 9 of 12 active firms rate RCUS a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RCUS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.88
Range $-1.00 – $-0.78 · 5 analysts · -13% YoY
Next period, 5 analysts expect Arcus Biosciences Inc to earn $-0.88 a share (range $-1.00 – $-0.78), versus $-1.02 a year earlier. Full-year consensus is $-3.48, growing to $-3.09 the year after.
REVENUE · NEXT QUARTER
$6.0M
Range $0 – $12.5M · 5 analysts · -65% YoY
Revenue is expected to reach $6.0M (range $0 – $12.5M), -64.5% year-over-year. Full-year consensus is $72.3M, rising to $55.8M next year.
Top analysts covering Arcus Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RCUS.
#1
Peter Lawson
Barclays · Rank #89
Buy
$14.00-11.3% to target
Overall win rate
45%
+ Follow
#2
Terence Flynn
Morgan Stanley · Rank #222
Neutral
$23.00+45.8% to target
Overall win rate
36%
+ Follow
#3
Li Watsek
Cantor Fitzgerald · Rank #357
Buy
No targeton RCUS
Overall win rate
38%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$50.00+216.9% to target
Overall win rate
38%
+ Follow
#5
Daina Graybosch
Leerink Partners · Rank #396
Buy
$47.00+197.8% to target
Overall win rate
41%
+ Follow
RCUS stock forecast FAQ
What is RCUS's average 12-month price target?+
The 11 active firms with a live target average $37.91 for Arcus Biosciences Inc over the next 12 months, ranging from a $49.00 high to a $22.00 low, as of Nov 20, 2026.
Is RCUS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 20, 2026, 9 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RCUS?+
The Street-high target is $49.00 (Leerink Partners), and the Street-low is $22.00 (Morgan Stanley). The average of all 11 active-firm targets is $37.91.
How many active Wall Street firms cover RCUS?+
12 active firms have a recognized rating on Arcus Biosciences Inc as of Nov 20, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RCUS?+
Among analysts who currently cover RCUS, Peter Lawson of Barclays has the strongest overall Quantellect track record (Rank #89). Their current call is Buy with a $14.00 target.
What is Arcus Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.88 per share (range $-1.00 – $-0.78) across 5 analysts. Full-year EPS is projected at $-3.48, rising to $-3.09 the following year.
How much revenue is Arcus Biosciences Inc expected to report next quarter?+
Consensus revenue is $6.0M (range $0 – $12.5M). Full-year revenue is projected at $72.3M, growing to $55.8M next year.
Have analysts been upgrading or downgrading RCUS lately?+
As of Nov 20, 2026, 9 of 12 active firms rate RCUS a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RCUS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.